Evidence map›Paper›PMID 31174481›Full record

Observational studyBMC infectious diseases2019

Clustering of leprosy beyond the household level in a highly endemic setting on the Comoros, an observational study.

Nimer Ortuno-Gutierrez, Abdallah Baco, Sofie Braet, Assoumani Younoussa, Aboubacar Mzembaba, Zahara Salim, Mohamed Amidy, Saverio Grillone, Bouke C de Jong, Jan Hendrik Richardus and 1 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Leprosy.Nature reviews. Disease primers · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Detection and Monitoring ofFrontiers in microbiology · 2021
    Article
  15. Leprosy surveillance study in a highly endemic Brazilian area using leprosy specific serologic tests and IFNγ whole blood assay.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Article
  16. Population Genomics ofFrontiers in microbiology · 2020
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Nimer Ortuno-GutierrezProjects Department, Damien Foundation, Boulevard Leopold II, 263, PO B-1081, Brussels, Belgium. Nimer.OrtunoGutierrez@damien-foundation.be.
Abdallah BacoNational Tuberculosis and Leprosy control Program, Moroni, The Union of, Comoros.
Sofie BraetInstitute of Tropical Medicine, Antwerp, Belgium.
Assoumani YounoussaNational Tuberculosis and Leprosy control Program, Moroni, The Union of, Comoros.
Aboubacar MzembabaNational Tuberculosis and Leprosy control Program, Moroni, The Union of, Comoros.
Zahara SalimNational Tuberculosis and Leprosy control Program, Moroni, The Union of, Comoros.
Mohamed AmidyNational Tuberculosis and Leprosy control Program, Moroni, The Union of, Comoros.
Saverio GrilloneNational Tuberculosis and Leprosy control Program, Moroni, The Union of, Comoros.
Bouke C de JongInstitute of Tropical Medicine, Antwerp, Belgium.
Jan Hendrik RichardusErasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Epco HaskerInstitute of Tropical Medicine, Antwerp, Belgium.
Instituut voor Tropische Geneeskunde · BEErasmus MC · NL

Funding

R2STOP R2STOP-COMLEP
6 · The paper itself

Abstract

backgroundThe island of Anjouan (Comoros) is highly endemic for leprosy with an annual incidence of 5-10/10,000. In May/June, 2015 single-dose Rifampicin post-exposure prophylaxis (SDR-PEP) was administered to 269 close contacts of 70 leprosy-patients in four villages as a pilot programmatic intervention. Two years later we revisited the villages for follow-up investigations. The main aim of our study was to quantify spatial associations between reported leprosy cases before and after PEP implementation. A secondary aim was to assess the effect of this single round of SDR-PEP at the individual level.

methodsWe conducted door-to-door leprosy screening in all four villages in August/September, 2017. We screened all consenting individuals for leprosy and recorded geographic coordinates of their household. We also recorded whether they had received SDR-PEP and whether they had been diagnosed with leprosy, before or after the 2015 intervention. We fitted a Poisson model with leprosy as outcome and distance to the nearest pre-intervention case and SDR-PEP as predictors.

resultsDuring the survey we found 114 new cases among 5760 contacts screened (2.0% prevalence), in addition to the 39 cases detected in the two preceding years. We found statistically significant associations of incident leprosy with physical distance to index cases ranging from 2.4 (95% confidence interval (95% CI) 1.5-3.6) for household contacts to 1.8 (95% CI 1.3-2.5) for those living at 1-25 m, compared to individuals living at ≥75 m. The effect of SDR-PEP appeared protective but did not reach statistical significance due to the low numbers, with an incidence rate ratio (IRR) of 0.6 (95% CI 0.3-1.2) overall, and 0.5 (95% CI 0.2-1.3) when considering only household contacts.

conclusionsThis pilot demonstrated an increased risk of leprosy in contacts beyond the household, therefore a wider circle should be considered for chemoprophylaxis. Baseline surveys and extended contact definitions are essential for improving SDR-PEP effectiveness.

Indexed as

Antibiotics, AntitubercularCluster AnalysisComorosHumansLeprosyPost-Exposure ProphylaxisPrevalenceRifampinAntibiotics, AntitubercularRifampinClusteringLeprosyMappingPost-exposure prophylaxisSingle dose rifampicinTransmission

Identifiers

PMID31174481
PMCPMC6556052
OpenAlexW2948605450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.